EMA recommends compassionate use of Gilead's remdesivir for COVID-19
April 03, 2020 at 09:16 AM EDT
The European Medicines Agency (EMA) on Friday recommended Gilead Sciences Inc's investigational antiviral drug remdesivir should be used for treating COVID-19 in compassionate use programmes.
